// App-Quantinova.ai

2508 : First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors.

Researchers

Presenter

  • David S. Hong

Principal Investigators

  • Patricia Lo Russo

  • Omid Hamid

  • Rui Tang

  • Gataree Ngarmchamnanrith

  • Rabia Khan

  • Muaiad Kittaneh

  • Robert D. Loberg

  • Benny Amore

  • Isaac Caudillo

  • Yuying C. Hwang

  • Eunice Lee Kwak

  • Darrin M. Beaupre

  • Filip Janku

Medical Centers

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Molecular Sciences and Computational Biology, Amgen Inc., Thousand Oaks, CA

  • Pharmacyclics, Inc., Sunnyvale, CA

  • Biostatistics - Medical Sciences, Amgen, Inc., Thousand Oaks, CAThe University of Texas MD Anderson Cancer Center, Houston, TXMassachusetts General Hospital Cancer Center, Boston, MA

  • Amgen, Seattle, WA

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Amgen Inc, Thousand Oaks, CA

  • The Angeles Clinic and Research Institute, Los Angeles, CA

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI

  • Amgen Inc, Thousand Oaks, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • AMG 337

Outcome

  • Indeterminate

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01253707

Sponsors

  • Pharmacyclics

  • Amgen

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved